516 related articles for article (PubMed ID: 12654251)
1. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
[TBL] [Abstract][Full Text] [Related]
2. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
Nagar B
J Nutr; 2007 Jun; 137(6 Suppl 1):1518S-1523S; discussion 1548S. PubMed ID: 17513418
[TBL] [Abstract][Full Text] [Related]
3. A myristoyl/phosphotyrosine switch regulates c-Abl.
Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
[TBL] [Abstract][Full Text] [Related]
4. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Schindler T; Bornmann W; Pellicena P; Miller WT; Clarkson B; Kuriyan J
Science; 2000 Sep; 289(5486):1938-42. PubMed ID: 10988075
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Nagar B; Bornmann WG; Pellicena P; Schindler T; Veach DR; Miller WT; Clarkson B; Kuriyan J
Cancer Res; 2002 Aug; 62(15):4236-43. PubMed ID: 12154025
[TBL] [Abstract][Full Text] [Related]
6. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
[TBL] [Abstract][Full Text] [Related]
7. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Lin YL; Meng Y; Jiang W; Roux B
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
[TBL] [Abstract][Full Text] [Related]
8. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
[TBL] [Abstract][Full Text] [Related]
9. A Src-like inactive conformation in the abl tyrosine kinase domain.
Levinson NM; Kuchment O; Shen K; Young MA; Koldobskiy M; Karplus M; Cole PA; Kuriyan J
PLoS Biol; 2006 May; 4(5):e144. PubMed ID: 16640460
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.
Lorenz S; Deng P; Hantschel O; Superti-Furga G; Kuriyan J
Biochem J; 2015 Jun; 468(2):283-91. PubMed ID: 25779001
[TBL] [Abstract][Full Text] [Related]
11. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
[TBL] [Abstract][Full Text] [Related]
12. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
Lin YL; Roux B
J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
[TBL] [Abstract][Full Text] [Related]
13. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck.
Yokoyama N; Miller WT
J Biol Chem; 2003 Nov; 278(48):47713-23. PubMed ID: 14506255
[TBL] [Abstract][Full Text] [Related]
14. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
[TBL] [Abstract][Full Text] [Related]
15. Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-cap.
Corbi-Verge C; Marinelli F; Zafra-Ruano A; Ruiz-Sanz J; Luque I; Faraldo-Gómez JD
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3372-80. PubMed ID: 23959873
[TBL] [Abstract][Full Text] [Related]
16. Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
Cheng WH; von Kobbe C; Opresko PL; Fields KM; Ren J; Kufe D; Bohr VA
Mol Cell Biol; 2003 Sep; 23(18):6385-95. PubMed ID: 12944467
[TBL] [Abstract][Full Text] [Related]
17. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
[TBL] [Abstract][Full Text] [Related]
18. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
Mol CD; Dougan DR; Schneider TR; Skene RJ; Kraus ML; Scheibe DN; Snell GP; Zou H; Sang BC; Wilson KP
J Biol Chem; 2004 Jul; 279(30):31655-63. PubMed ID: 15123710
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
